|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.81 EUR | -2.40% |
|
-4.50% | -11.66% |
| May. 30 | Healthcare Stocks Rise -- Healthcare Roundup | DJ |
| May. 30 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
Summary: Sanofi
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Sanofi
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: Sanofi
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The group usually releases earnings worse than estimated.
Ratings Chart: Sanofi
Source: Surperformance
ESG chart: Sanofi
Source: MSCI
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| 119B | |||||
| 710B | |||||
| 367B | |||||
| 335B | |||||
| 328B | |||||
| 258B | |||||
| 230B | |||||
| 223B | |||||
| 197B | |||||
| 156B | |||||
| Average | 292.17B | ||||
| Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
BBB
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SAN Stock
- Ratings Sanofi
Select your edition
All financial news and data tailored to specific country editions
